Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 6
Submit an article Journal homepage
236
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all ‘non-adverse’ risk AML

Abdullah Ladhaa Division of Hematology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA
,
Gavin Huib Department of Medicine, Stanford University, Stanford, CA, USA
,
Edna Cheungc Department of Pharmacy, Stanford Health Care, Stanford, CA, USA
,
Caroline Berubed Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA
,
Steven E. Coutred Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA
,
Jason Gotlibd Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA
,
Michaela Liedtked Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA
,
Tian Y. Zhangd Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USAORCID Iconhttps://orcid.org/0000-0002-6274-0763
ORCID Icon,
Lori Mufflye Division of Blood and Marrow Transplantation, Stanford Cancer Institute, Stanford University, Stanford, CA, USA
&
Gabriel N. Mannisd Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USACorrespondence[email protected]
 show all
Pages 1510-1513 | Received 20 Nov 2020, Accepted 07 Jan 2021, Published online: 24 Jan 2021

References

  • Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011;17(20):6417–6427.
  • Food and Drug Administration. Gemtuzumab approval letter; 2000, May 17. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21174_MYLOTARG_APPROV.PDF.
  • Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–4860.
  • Food and Drug Administration. FDA approves Gemtuzumab Ozogamicin for CD33 positive AML; 2017, September 1. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gemtuzumab-ozogamicin-cd33-positive-AML.
  • Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508–1516.
  • Daver N, Kantarjian H, Ravandi F, et al. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 2016;30(2):268–273.
  • Borthakur G, Cortes JE, Estey EE, et al. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014;89(10):964–968.
  • Hills RK, Castaigne S, Appelbaum FR, et al. The addition of gemtuzumab ozogamicin to induction chemotherapy in acute myeloid leukaemia: an individual patient data meta-analysis of randomised trials in adults. Lancet Oncol. 2014;15(9):986–996.
  • Schlenk RF, Paschka P, Krzykalla J, et al. Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: Early results from the prospective randomized AMLSG 09-09 phase III study. J Clin Oncol. 2020;38(6):623–632.
  • Herold T, Rothenberg-Thurley M, Grunwald VV, et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2020;34(12):3161–3172.
  • National Comprehensive Cancer Network Clinical Practice Guideline on Acute Myeloid Leukemia Version 1.2021; 2020, October 14. Available from: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf.
  • Lambert J, Pautas C, Terré C, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104(1):113–119.
  • Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, et al. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. 2020;95(9):E225–E228.
  • Röllig C, Kramer M, Schliemann C, et al. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood. 2020;136(7):823–830. Jun 4.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.